ACT 128800

Name	(2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one
Synonyms	CS-2110 PONESIMOD PonesiMod ACT 128800 PONESIMOD,ACT-128800 Ponesimod ( ACT-128800) (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one 5-[3-Chloro-4-[((2R)-2,3-dihydroxypropyl)oxy]benz-(Z)-ylidene]-2-((Z)-propylimino)-3-(o-tolyl)thiazolidin-4-one (5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one 4-Thiazolidinone, 5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]Methylene]-3-(2-Methylphenyl)-2-(propyliMino)-, (2Z,5Z)-
CAS	854107-55-4

Molecular Formula	C23H25ClN2O4S
Molar Mass	460.97
Density	1.30±0.1 g/cm3(Predicted)
Boling Point	658.0±65.0 °C(Predicted)
pKa	13.38±0.20(Predicted)
Storage Condition	2-8℃
In vitro study	Relative to the potency of S1P, ponesimod had a 4.4-fold higher regulatory efficacy on the human recombinant receptor S1P1 and a 150-fold lower regulatory efficacy on S1P3. Thus, ponesimod is approximately 650-fold more selective for S1P1 than the natural ligand relative to S1P3.
In vivo study	Ponesimod is a novel, potent and selective S1P1 receptor agonist. Ponesimod prevents edema formation, accumulation of inflammatory cells, and release of cytokines in the skin of delayed-type allergic mice. Ponesimod can prevent the increase of toe volume and joint inflammation in rats with adjuvant arthritis. Selective activation of S1P1 with ponesimod leads to a decrease in the number of peripheral blood lymphocytes and prevents lymphocyte-mediated tissue inflammation. ponesimod may exert its utility in animal models of autoimmunity and human autoimmune diseases through its effect on T cell and B cell blood cell numbers. Thus, ponesimod may be a new therapeutic option for the treatment of autoimmune diseases. Within one week after discontinuation of treatment, Ponesimod was eliminated and its medicinal effect was rapidly reversible.